A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Epithelial ovarian cancer is the most lethal gynecologic malignancy, and most patients eventually relapse and develop resistance to available therapies. Immune checkpoint inhibitors have shown limited overall efficacy in recurrent ovarian cancer, partly because of its immunosuppressive tumor microenvironment. Manganese (Mn2+) can activate the cGAS-STING pathway and may enhance antitumor immunity and the therapeutic effects of PD-1 blockade combined with chemotherapy. Following encouraging findings from an early-phase study, a randomized, single-blind, placebo-controlled phase II trial showed that the addition of manganese chloride to anti-PD-1 antibody, nab-paclitaxel, and cisplatin improved clinical outcomes compared with placebo, with an overall manageable safety profile. Based on these findings, this phase III trial is designed to confirm the efficacy and further evaluate the safety of Mn2+-primed immunochemotherapy in patients with advanced ovarian cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie lub cytologicznie rak jajnika, rak jajowodu lub rak otrzewnej
- •Wcześniejsze leczenie przynajmniej dwiema liniami terapii, w tym co najmniej jedną z platną
- •Nowotwór progresywny podczas lub w ciągu 6 miesięcy po ostatnim leczeniu
- •Co najmniej jedno widoczne ognisko nowotworu
- •Przewidywana przeżywalność powyżej 6 miesięcy
- •Wiek powyżej 18 lat
- •Waga powyżej 40 kg
- •Dobry ogólny stan zdrowia pozwalający na podjęcie leczenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 16, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (6)
Department of Obstetrics and Gynecology, Seventh Medical Center, Chinese PLA General Hospital
Beijing, China
Department of Bio-therapeutic, First Medical Center, Chinese PLA General Hospital
Beijing, China
Department of Obstetrics and Gynecology, First Medical Center, Chinese PLA General Hospital
Beijing, China
Peking University International Hospital
Beijing, China
Department of Obstetrics and Gynecology, North China University of Science and Technology Affiliated Hospital
Tangshan, China
Department of Gynecologic Oncology, Shanxi Province Cancer Hospital
Taiyuan, China
Trial contact
Weidong Han
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.